SCHEMBL23291908

SCHEMBL23291908

Cc1nc(-c2ccc(CNc3cnccn3)cc2F)no1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 13/20 0.51
HDAC6 Q9UBN7 13/20 0.51
HDAC5 Q9UQL6 11/20 0.51
HDAC8 Q9BY41 9/20 0.51
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 4/20 0.50
HPGD P15428 4/20 0.50
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30172420 1.00 HDAC1 (0.51) HDAC1HDAC6HDAC5HDAC8ALDH1A1
SCHEMBL23780448 0.85 HDAC1 (0.72) HDAC1HDAC6HDAC5HDAC8
SCHEMBL30172354 0.85 HDAC1 (0.72) HDAC1HDAC6HDAC5HDAC8
SCHEMBL23780442 0.82 HDAC1 (0.69) HDAC1HDAC6HDAC8ALDH1A1KDM4E
SCHEMBL23780462 0.78 HDAC1 (0.51) HDAC1HDAC6HDAC8ALDH1A1KDM4E
SCHEMBL23291921 0.69 ALDH1A1 (0.63) HDAC1HDAC6HDAC8ALDH1A1KDM4E
SCHEMBL3956196 0.68 ALDH1A1 (1.00) HDAC1HDAC6HDAC8ALDH1A1KDM4E
SCHEMBL4141061 0.68 ALDH1A1 (1.00) HDAC1HDAC6HDAC8ALDH1A1KDM4E
SCHEMBL14363635 0.68 L3MBTL1 (0.47) HDAC1HDAC6ALDH1A1KDM4EHPGD
SCHEMBL12112396 0.68 L3MBTL1 (0.47) HDAC1HDAC6HDAC5HDAC8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP claimed
US-12187712-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2025-01-07 US disclosed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP disclosed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP disclosed
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-09-09 US disclosed
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-09-09 US disclosed
EP-3814343-A1 CARDIAC SARCOMERE INHIBITORS Cytokinetics, Inc. (US) 2021-05-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187712-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 HDAC1 203/4885HDAC6 233/4885HDAC5 710/4885
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 HDAC1 203/4885HDAC6 233/4885HDAC5 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.